News

Partnership to build a platform for the development of safer and more efficient genetic engineering of human cells for cell therap...

BlueRock Therapeutics and bit.bio announce collaboration and option agreement for the discovery & manufacture of regulatory T cell...

bit.bio secures foundational United States patent for opti-ox, its cell programming technology that uses genomic safe harbour site...

bit.bio launches two new human cell disease models to advance discovery and development of treatments for Duchenne muscular dystro...

Industrialising human cell manufacturing will unleash the potential of synthetic biology for reproducible research and affordable ...

Offering will provide robust, standardised tools for research and drug discovery.

Weslie Janeway - investor, philanthropist, and scientist - joins bit.bio's Board of Directors.

This collaboration will combine the Mekonos novel ex vivo delivery platform with bit.bio’s opti-ox precision cellular reprogrammin...